Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
Although Wnt/beta-catenin pathway activation has been implicated in mouse models of breast cancer, there is contradictory evidence regarding its importance in human breast cancer. In this study, invasive and in situ breast cancer tissue microarrays containing luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)(+)/ER(-) and basal-like breast cancers were analyzed for beta-catenin subcellular localization. We demonstrate that nuclear and cytosolic accumulation of beta-catenin, a read-out of Wnt pathway activation, was enriched in basal-like breast cancers. In contrast, membrane-associated beta-catenin was observed in all breast cancer subtypes, and its expression decreased with tumor progression. Moreover, nuclear and cytosolic localization of beta-catenin was associated with other markers of the basal-like phenotype, including nuclear hormone receptor and HER2 negativity, cytokeratin 5/6 and vimentin expression, and stem cell enrichment. Importantly, this subcellular localization of beta-catenin was associated with a poor outcome and is more frequently observed in tumors from black patients. In addition, beta-catenin accumulation was more often observed in basal-like in situ carcinomas than other in situ subtypes, suggesting that activation of this pathway might be an early event in basal-like tumor development. Collectively, these data indicate that Wnt/beta-catenin activation is an important feature of basal-like breast cancers and is predictive of worse overall survival, suggesting that it may be an attractive pharmacological target for this aggressive breast cancer subtype.
Khramtsov
Andrey I
AI
University of Chicago, Department of Medicine, Chicago, IL 60637, USA.
Khramtsova
Galina F
GF
Tretiakova
Maria
M
Huo
Dezheng
D
Olopade
Olufunmilayo I
OI
Goss
Kathleen H
KH
D000328:Adult; D000368:Aged; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D051379:Mice; D046228:Microarray Analysis; D008875:Middle Aged; D018295:Neoplasms, Basal Cell / Q000378:metabolism* / Q000473:pathology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D015996:Survival Rate; D051153:Wnt Proteins / Q000378:metabolism*; D051176:beta Catenin / Q000378:metabolism*
D015415:Biomarkers; D018719:Erb-b2 Receptor Tyrosine Kinases; D051153:Wnt Proteins; D051176:beta Catenin
Nat Cell Biol. 2001 Sep;3(9):793-801
11533658
J Mol Histol. 2007 May;38(2):113-21
17318343
J Cell Sci. 2007 Feb 1;120(Pt 3):468-77
17227796
Am J Pathol. 2002 Sep;161(3):1087-97
12213737
Cancer. 2007 May 1;109(9):1721-8
17387718
Carcinogenesis. 2000 Nov;21(11):1935-40
11062151
J Pathol. 2001 Apr;193(4):433-41
11276001
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6
10759547
Cell. 1987 Aug 14;50(4):649-57
3111720
J Pathol. 2007 Mar;211(4):389-98
17212342
Br J Cancer. 2002 Nov 18;87(11):1281-6
12439718
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23
17202265
Cell. 1988 Nov 18;55(4):619-25
3180222
Breast Cancer Res. 2008;10(3):R53
18559090
Cancer Cell. 2004 Jan;5(1):91-102
14749129
Biometrics. 1994 Dec;50(4):933-44
7787006
Cell. 2006 Nov 3;127(3):469-80
17081971
Histopathology. 2000 Apr;36(4):313-25
10759945
Breast Cancer Res Treat. 2005 Apr;90(3):249-56
15830138
Cancer Res. 2003 May 15;63(10):2658-64
12750294
Cancer Res. 2008 Feb 15;68(4):989-97
18281472
Nat Med. 1998 Jul;4(7):844-7
9662379
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
17438091
Nat Clin Pract Oncol. 2008 Mar;5(3):149-59
18212769
Cancer. 2004 May 15;100(10):2084-92
15139049
Nature. 2000 Aug 17;406(6797):747-52
10963602
Cells Tissues Organs. 2007;185(1-3):191-203
17587825
J Cancer Res Clin Oncol. 1999;125(5):297-304
10359135
J Pathol. 2002 Feb;196(2):145-53
11793365
Mod Pathol. 2006 May;19(5):617-21
16528377
Cancer Res. 2006 May 15;66(10):5487-94
16707478
Clin Cancer Res. 2008 Jul 1;14(13):4038-44
18593979
Cancer Res. 1990 Nov 1;50(21):7057-61
2208173
Virchows Arch. 1997 Sep;431(3):167-72
9334837
J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):145-58
14635791
Histol Histopathol. 2009 Mar;24(3):385-98
19130408
J Cell Sci. 2005 Aug 15;118(Pt 16):3585-94
16105882
J Clin Pathol. 1993 Feb;46(2):189-90
8459046
PLoS One. 2009;4(3):e4968
19319191
Eur J Surg Oncol. 2001 Feb;27(1):31-6
11237489
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7
15314234
Cancer Res. 2009 May 15;69(10):4116-24
19435916
J Clin Oncol. 2007 Jan 1;25(1):118-45
17159189
J Pathol. 1998 Jul;185(3):262-6
9771479
JAMA. 2006 Jun 7;295(21):2492-502
16757721
Br J Cancer. 1999 Jun;80(7):1046-51
10362114
Am J Pathol. 1998 Jan;152(1):75-82
9422525
Mod Pathol. 2006 Nov;19(11):1506-11
16941011
BMC Genomics. 2006 Apr 27;7:96
16643655